Compare AST SpaceMobile Inc (ASTS) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AST SpaceMobile Inc vs Johnson & Johnson — how do they compare? AST SpaceMobile Inc trades at $67.63 (market cap $21.90B), while Johnson & Johnson trades at $257.87 (market cap $618.61B). The key difference: Johnson & Johnson is far larger — about 28.2× AST SpaceMobile Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while AST SpaceMobile Inc pays none. Which is the better fit depends on your goals.
| ASTS | JNJ | |
|---|---|---|
Market Cap | $21.90B | $618.61B |
Sector | Media | Health |
52-Week High | $133.09 | $267.24 |
52-Week Low | $36.91 | $155.17 |
Enterprise Value | $21.87B | $651.54B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASTS trades at $73.32, down 0.76% on the day, with a bearish technical signal from moving averages and mixed oscillators. The company reported revenue of $70.92 million in 2025 but sustained a net loss of $341.94 million, missing earnings expectations for three consecutive quarters. Recent news highlights potential in defense communications via satellite technology, though competition with SpaceX remains a focal point.
The outlook is speculative with high execution risk; analyst consensus is divided with a $90.33 price target. Investment opportunity hinges on successful satellite deployment and partnership execution, but persistent losses and intense competition pose significant downside risks for shareholders.
Johnson & Johnson (JNJ) trades at $256.98, down 0.82% today, with a bullish technical signal from moving averages and a consensus analyst price target of $268.50. The company reported strong Q1 2026 EPS of $2.70, beating expectations, and maintains robust profitability with a net income margin of 21.83%. Recent news highlights dividend growth strategies and comparisons with peers like AbbVie, while cash flow trends show operational strength despite negative net cash flow in 2025.
JNJ presents a stable investment opportunity with consistent earnings beats and a solid dividend, but faces risks from rising debt levels and competitive pressures. The stock's current valuation metrics, including a P/E of 29.78, suggest it is fairly valued with moderate upside potential based on analyst targets. Investors should weigh the company's strong fundamentals against macroeconomic and sector-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AST SpaceMobile Inc
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building the global cellular broadband network in space to operate directly with standard, unmodified mobile devices based on extensive IP and patent portfolio. AST is on a mission to eliminate the connectivity gaps faced by mobile subscribers and finally bring broadband to the billions who remain unconnected.
Read more on ASTS →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
